The abundance and functional orientation of tumor-infiltrating lymphocytes in breast cancer is associated with distant metastasis-free survival, yet how this association is influenced by tumor phenotypic heterogeneity is poorly understood. Here, a bioinformatics approach defined tumor biological attributes that influence this association, and delineated tumor subtypes that may differ in their ability to sustain 
INTRODUCTION
As cancer cells emerge and propagate, they must acquire evasive tactics to escape immune destruction. These tactics must endow malignant cells with the ability to avoid elimination by the immune system early in their formation, establish equilibrium with the immune system as the tumor grows, and eventually escape from immune control enabling tumor progression (1) . However, results from both mechanistic and correlative studies indicate that some established tumors, with or without therapeutic intervention, can eventually succumb to immune control by establishment of a helper T cell type 1 (Th1)-type immune response that mediates tumor rejection and gives rise to immunological memory that guards against future metastases (2) (3) (4) . Consistent with these observations, numerous histological studies have demonstrated that the abundance and functional orientation of tumor-infiltrating effector cells within primary tumors can significantly predict recurrence-free survival of cancer patients (5) . This is particularly true of cancers of the breast, colon, ovary, lung, liver, head/neck, skin and brain, whereby abundant tumor-infiltrating lymphocytes (TIL), namely cytotoxic T cells (CTLs), memory T cells, natural killer (NK) and NKT cells, have been associated with the suppression of metastatic recurrence (5) (6) (7) . Together, these findings suggest that: 1) abundant tumor infiltration by effector cells is indicative of an antitumor immune response, and 2) the induction of tumor-reactive immunity capable of guarding against metastatic progression is a fairly common event in multiple cancer types.
Microarray tumor profiling studies are now providing compelling evidence that the relative abundance of tumor-infiltrating immune cells can be quantified by the surrogate measure of intratumoral transcript levels of immune cell-specific genes that are coordinately-expressed (8) (9) (10) (11) (12) (13) . Through hierarchical clustering analysis, we and others have demonstrated that these genes self-organize into multiple gene clusters that embody signaling networks fundamental to distinct and identifiable immune cell subpopulations (12) (13) (14) (15) (16) (17) (18) . These immune gene signatures or "metagenes", consistent with the effector cell types they reflect, have been shown by multiple groups to be associated with patient outcomes such as disease-free and overall survival (2, 8, 12, 13, 16, (19) (20) (21) , response to neoadjuvant chemotherapy (22, 23) and adjuvant molecular therapy (anti-Her2/neu) (24) paralleling historical immunohistochemical observations.
We characterized the underlying biology and prognostic ramifications of several distinct immune metagenes in breast cancer (12) . The term "metagene" is defined here as a cluster of coordinately-expressed genes that together comprise a single cognate expression vector. By averaging the expression levels of these genes, a composite expression score can be computed for each tumor (25) . We showed that the immune metagene scores quantify the relative abundance of distinct effector cell populations, namely cytotoxic T and/or NK cells (the T/NK metagene), antibody-producing plasma B cells (the B/P metagene), and antigen-presenting myeloid/dendritic cells (the M/D metagene). The expression scores of all three metagenes were significantly associated with prolonged distant metastasis-free survival (DMFS) of breast cancer patients and displayed additive prognostic information when considered in multivariate Cox regression models. We have also observed that these same prognostic immune metagenes are predictive of taxane and anthracycline efficacy in the neoadjuvant setting (22) .
Although the density of immune effector cell infiltrates represents a significant prognostic marker, it does not comprehensively characterize the immune system's functional orientation towards cancer. For even in the presence of abundant TIL, some tumors still escape immune destruction and progress to metastatic disease. Why effector immune infiltrates equate with protective antitumor immunity in some cancers but not others could depend on one or more immunomodulatory mechanisms acting alone or in concert. A better understanding of which tumors will and will not give rise to productive immunity could serve as a valuable predictor of immunotherapy responsiveness as well as create opportunities to discover and model causal mechanisms of pro-and antitumor immunity in specific cancer types.
In breast cancer, we previously observed that the immune metagenes exhibited clear prognostic power in some tumors, but not others. We found that a gene signature highly correlated with tumor cell mitotic index and Ki67 staining (termed the "proliferation", or "P" metagene) enabled the stratification of breast tumors into subgroups that either permitted or prohibited prognostication by the different immune metagenes (12 system may be governed, in part, by certain definable tumor characteristics associated with intrinsic tumor immunogenicity.
In this study, we address the question of how to optimally stratify breast tumors into subsets that differ in their potential for protective immune responsiveness. Although a number of immunohistochemical and microarray-based studies have analyzed the protective effects of relative levels of immune infiltration in breast cancer, none have addressed the question of how to distinguish tumors where elevated immune involvement does or does not confer protective benefit. We hypothesized that the statistical association between the immune metagenes and DMFS of patients could be used as a means to extrapolate the underlying breast tumor phenotypes that differ in their ability to potentiate long-term, immune-mediated tumor rejection. Using an immune metagene model that combines the prognostic attributes of the B/P, T/NK and M/D metagenes, we define and validate proliferative and intrinsic subtype attributes of breast cancer that indicate the existence of immune benefit-enabled (IBE) and immune benefitdisabled (IBD) tumor subtypes, and shed light on the underlying molecular pathways that may contribute to their differing immunogenic dispositions.
MATERIALS AND METHODS
Microarray Datasets and Data Processing. All microarray data were obtained from MIAME-compliant (26) data repositories and were associated with institutional review board (IRB)-approved specimen collection protocols compliant with REMARK criteria (27) . The meta-cohort #1 (MC1) dataset comprised of 1,954 tumor expression profiles of primary invasive breast cancer generated on the Affymetrix U133 series GeneChip (12) . Briefly, the data represent diverse patient populations spanning 16 medical centers in the U.S., Europe and Asia. Raw data (CEL files) were extracted from the NCBI's Gene Expression Omnibus (GEO) (28) (accessions: GSE1456, GSE2034, GSE5327, GSE12093, GSE7390, GSE6532, GSE9195, GSE2603, GSE7378, GSE8193, GSE4922, GSE11121, and GSE45255), the NCI's caArray database (accession: mille-00271), and the EMBL-EBI's ArrayExpress database (accession: E-TABM-158). The meta-cohort #2 (MC2) dataset consisted of 616 breast tumor expression profiles derived from patients in the U.S., Asia, Europe and New Zealand.
Samples were analyzed on the same Affymetrix platforms as MC1, and CEL files were accessed via GEO accessions: GSE19615, GSE20685, GSE31519 and GSE36771.
For MC1 and MC2, all CEL files were pre-processed and normalized using the R software package (29) and library files provided by the Bioconductor project. Array data were MAS5.0 normalized using the justMAS function in the simpleaffy library from Bioconductor (30) using a trimmed mean target intensity of 600 without background correction. Non-biological batch effects were corrected using the COMBAT empirical 524 cases/profiles. Intrinsic molecular subtype calls for the TCGA data were utilized as previously generated (32) . For MC1 and MC2 meta-cohorts, molecular subtype calls were assigned according to (12) . al. (12) . In the MC2 and TCGA cohorts, metagene scores were computed as described Clinical endpoints and censoring criteria related to distant metastasis-free survival were applied as described in (12) . In the multivariable models, covariates were entered as semi-continuous variables. A stepwise covariate selection procedure was used with entry significance level 0.05. Likelihood ratio test P-values were reported. For analysis of cell type-specific marker genes in IBE and IBD populations, Affymetrix probe sets were processed as described in Supplementary Methods. Differential gene expression analysis. Microarray probe sets (n=22,268) were analyzed for differential gene expression between the IBE-FID (n=179) and IBD-FID (n=135) tumor subtypes. The two-tailed Student's t-test (unequal variance) with false discovery correction (Benjamini-Hochberg) was used to assess the significance of gene differential expression. Probe sets having false discovery rates <1% (q<0.01) and absolute value of log 2 fold-change >0.50 were selected for downstream analyses.
Patient and
Pathway activation scores were generated as described previously (33) influenced, to variable degrees, the prognostic potential of the individual immune metagenes (12) . Therefore, we employed Cox proportional hazards regression to determine the prognostic relevance of the IMM within each molecular subtype stratified according to proliferative capacity via proliferation metagene tertiles (Supplementary Table S2 Fig. S4A and B) . This indicates that the LumA subtype is not driving the negligible immune-prognostic characteristic of IBD. Together, these observations suggest that prominent immune infiltrate associated with FID tumors can guard against metastatic progression in some tumor subtypes (IBE), but not others (IBD).
To discern the prognostic value of the IMM in the presence of conventional variables, we fit a stepwise Cox proportional hazards model within IBE and IBD to elucidate independent associations with DMFS ( Table 1) . In IBE tumors, the IMM and lymph node status were each significant univariably, with only the IMM and tumor size remaining significant after adjusting for other variables. In contrast, in IBD tumors, histologic grade, tumor size, lymph node status, age, and ER status were each individually significant, with histologic grade, tumor size, lymph node status and adjuvant treatment remaining significant after adjustment. These findings suggest that in IBE tumors the IMM adds substantial prognostic information to conventional prognostic markers, and that the significant prognostic stratification conferred by the IMM in IBE tumors is not a spurious event driven by other known associations.
IBE and IBD are reproducible disease states
To validate our parameters for defining IBE and IBD, we sought to confirm their existence using microarray datasets from two independent patient populations: MC2 and TCGA. MC2 (Meta-Cohort #2) comprises 616 breast tumors profiled on the Affymetrix U133 series GeneChips, whereas the TCGA cohort comprises 524 breast tumors profiled on an Agilent custom microarray as part of the Cancer Genome Atlas project (32) . Using the same procedures employed in MC1, we assigned tumors of MC2 and TCGA to metagene tertiles, IMM subclasses and PAM50 subtypes. We then categorized tumors as IBE or IBD according to MC1-defined thresholds and examined 
the prognostic performance of the IMM subclasses by Kaplan-Meier analysis. In the MC2 cohort, the prognostic performance of the IMM was highly significant in the IBEdesignated tumors, stratifying patients into markedly different DMFS risk groups ( Fig.   2A) . By contrast, the IMM failed to risk stratify patients in the IBD-designated tumors (Fig. 2B) . In the TCGA cohort, the IMM again exhibited statistical significance in the tumors classified as IBE (Fig. 2C) , but not IBD (Fig. 2D) Fig. S4C and D) , despite the lower proliferative capacity of IBD tumors in general.
Thus, we investigated the transcriptional differences that distinguish IBE-FID from IBD- Consistent with the prognostic observations, a number of these genes were found to be statistically significantly overexpressed in IBE-FID tumors, including genes involved in Th1 polarization (IFNG, IRF1, STAT1 ), cell-mediated cytotoxicity (GZMB, GNLY, PRF1, GZMH), antitumor chemoattraction (CXCL9, CXCL10, CX3CL1, CCL5) and leukocyte adhesion (ICAM1). Positive regulators of CTL activation-including CTLA4, CD80, and CD86-were also overexpressed in IBE-FID. Conversely, we observed that TGFB1, encoding the immunosuppressive cytokine TGF-beta, was overexpressed in IBD-FID tumors. Using an unsupervised approach, we applied Gene Ontology (GO) enrichment analysis to the genes significantly differentially expressed between IBE-FID and IBD-FID using the DAVID Bioinformatics Resource (38, 39) . Controlling for false discoveries, we identified 460 and 569 probe sets significantly overexpressed in IBE-FID and IBD-FID tumors, respectively. As anticipated, we found that many genes overexpressed in IBE-FID tumors were significantly associated with the GO terms cell cycle transit, cell division and proliferation, consistent with the IBE subtype comprising mostly of highly proliferative tumors. Specifically, we found that 38% of the IBE-FID-overexpressed probe sets were correlated with the proliferation metagene at R>0.5. After adjusting for these cell cycle-associated genes and analyzing for GO enrichment, one annotation cluster of significantly enriched terms was related to immunological processes, namely chemokine activity (P = 7.3 x 10 of GO terms such as secreted (P < 0.0001), extracellular matrix (P < 0.0001), skeletal system development (P < 0.0001), and cell adhesion (P < 0.0001). Within these categories were genes representing more distinct biological processes such as The contemporary view of breast cancer as poorly immunogenic is predicated on the absence of an observed increase in breast cancer incidence in immunocompromised patients and lack of responsiveness to otherwise clinically effective immunotherapy (41) . Nonetheless, mounting evidence from studies of breast cancer-specific immune responses suggest variable immunogenic activity (42, 43) . Recently, the immune contexture of breast cancer has gained broad acceptance as an important clinical correlate in both patient prognosis and therapy prediction. An understanding of how the prognostic value of immune infiltrates varies across the spectrum of breast tumor subtypes is relevant to disease management and can provide much needed biological insight into the underlying variation in tumor immunogenicity. To this point, we hypothesized that breast tumor immunogenicity, like other biological properties of cancer, is subject to phenotypic heterogeneity, varying from tumor to tumor according to molecular cues intrinsic to cancer cells or to other components of the tumor microenvironment. Our findings suggest that the immunogenic heterogeneity of human breast cancer may be resolved, to a substantial degree, by the molecular classification of breast tumors into two discernible subtypes that vary on both clinical and biological scales. We show that these subtypes, termed immune benefit-enabled (IBE) and 
angiogenesis (BMP4, CTGF, SLIT2, SLIT3, LEPR, EMCN, FGF18, PLXDC1, EGFL7, CXCL12), proteolysis (ADAM12, ADAM23, MMP28, PLAT, CPE, CPZ, C4A, C7, CFD, HTRA1, AEBP1, PCSK5, TPSAB1), TGF-beta signaling (TGFBR3, BMP4, BMPR1B, THBS4, DCN, CHRD, COMP) and response to wounding (C7, C4A, CFD, CTGF, EPHA3, IGF1, IGF2, IGFB4, LAMB2, LYVE1, MMRN1, THBD, TIMP3, VWF).
features of IBE and IBD are differential measures of proliferative capacity and composition of intrinsic molecular subtype, and as such provide a reproducible classification system for delineating IBE and IBD (Fig. 2) .
Our data indicate that IBD are least likely to be controlled by immune infiltrates perhaps because their functional orientation is less clearly polarized towards a Th1/effector phenotype as supported by evidence in Tables 2 and 3 . Expression of CD8 did not significantly differ between IBE and IBD ( Table 2 ), suggesting that the functional molecular orientation is the key determinant of these opposite phenotypes.
The results of a gene network analysis suggest that some of the phenotypic characteristics may be related to the production by IBD tumors of potent immune suppressant factors, such as TGFβ, that may alter the functional status of the immune response in the tumor microenvironment, though this hypothesis remains to be confirmed. Recent new evidence suggests that in some breast tumors, TGFβ signaling (in association with Smad3) contributes to the maintenance of an anti-proliferative effect manifesting as a reduced tumor proliferative capacity (44) . Thus, the potential duality of TGFβ function, as an intrinsic tumor suppressor and potent immunosuppressive cytokine could explain, in part, the low-proliferative phenotype of IBD tumors in general, and an impaired immune response associated with IBD-FID, specifically.
In contrast, our findings suggest that IBE tumors are endowed with the potential to achieve a metastasis-protective immune response (in the FID subclass) that may be facilitated by a proclivity toward Th1 polarization ( Table 2 ) via activation of TNFα and/or IFNγ signaling (Table 3) the factors that regulate antitumor immunity with the potential to spark novel therapeutic strategies that target specific immunogenic subtypes. 
